UPDATE: Pfizer Announces New Long-Term Relapse Prevention Data For PRISTIQ® (desvenlafaxine) 50 mg/day For The Treatment Of Major Depressive Disorder In Adults

Pfizer Inc.

announced new data presented at the 165th Annual Meeting of the American Psychiatric Association (APA) in Philadelphia on PRISTIQ® (desvenlafaxine) Extended Release Tablets 50 mg/day for the treatment of major depressive disorder (MDD) in adults,1 including a long-term relapse prevention study. These new data, and data from a study in peri- and post-menopausal women with MDD, add to the existing efficacy and safety profile of PRISTIQ for the treatment of MDD. Lastly, new data also provide information regarding the discontinuation of PRISTIQ 50 mg/day for the treatment of adults with MDD.2,3,4 Pfizer has continued to research and evaluate PRISTIQ, a selective serotonin and norepinephrine reuptake inhibitor (SNRI), since it was approved by the U.S. Food and Drug Administration (FDA) in 2008 for the treatment of MDD in adults.1 These new PRISTIQ 50 mg/day data focus on key factors – efficacy, safety, long-term use and discontinuation – that clinicians often consider when assessing antidepressants for the treatment of MDD. “Patients benefit when their healthcare providers have a variety of medicines from which to choose for complex medical conditions, such as major depressive disorder,” said Christine Guico-Pabia, M.D., MBA, M.P.H., senior director, Global Medical Affairs at Pfizer. “Millions of patients continue to seek relief from their depression and may look to different treatment options. With an established efficacy and safety profile, and new data that provide clinicians with valuable treatment insights, there is a robust body of evidence that supports the use of PRISTIQ for adult patients with major depressive disorder.”